Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE0006599905
Tue, 05.12.2023
Merck KGaA
Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis ("RMS") in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the "Clinical Trials"). Both Clinical T [ … ]
Wed, 03.11.2021
Merck KGaA
Darmstadt, November 3, 2021. Based on a very strong third quarter of 2021 with net sales of EUR 4.97 bn resulting in EBITDA pre1 of EUR 1.55 bn and EPS pre1 of EUR 2.24, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2021. The main driver is a very strong operating performance from the Life Science busine [ … ]
Tue, 04.05.2021
Merck KGaA
Darmstadt, 4 May 2021. Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre1 of EUR 1.51 bn and EPS pre1 of EUR 2.18, Merck KGaA (the "Company") has raised its forecast for the entire group for fiscal 2021. The Company now projects net sales of ap [ … ]
Wed, 20.01.2021
Merck KGaA
Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers.
While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) t [ … ]
Tue, 29.09.2020
Merck KGaA
Darmstadt, September 29, 2020. In the United States Merck KGaA's subsidiary EMD Serono, Inc. (Merck) is involved in a US patent dispute with Biogen Inc., United States (Biogen). Biogen sued Merck for damages in connection with a patent infringement caused by Merck's product Rebif before the U.S. District Court New Jersey, Newark. Merck defended its [ … ]